TransCode Therapeutics (NASDAQ:RNAZ) Posts Earnings Results

TransCode Therapeutics (NASDAQ:RNAZ) announced its earnings results on Friday. The company reported ($7.17) EPS for the quarter, FiscalAI reports.

TransCode Therapeutics Stock Down 5.7%

RNAZ stock traded down $0.20 during mid-day trading on Friday, reaching $3.28. The company’s stock had a trading volume of 40,808 shares, compared to its average volume of 17,396. TransCode Therapeutics has a fifty-two week low of $3.21 and a fifty-two week high of $20.99. The company’s 50 day moving average is $6.05 and its two-hundred day moving average is $7.67.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of TransCode Therapeutics in a research note on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.